Court proceedings initiated for immediate market approval of Brixadi™ in the US
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product.
Camurus’ partner, Braeburn Inc., has initiated court proceedings foran approval of Brixadi (Buvidal® in the US) and to overturn the 3-year market exclusivity granted by the FDA to another product. Buvidal is approved for the treatment of opioid dependence in the EU and Australia.
Read more at Camurus’ website: https://www.camurus.com/pressreleases/
Latest news
2020-12-14
Camurus announces outcome of the arbitration process with Braeburn.
Camurus announced on December 10, 2020, that the ICC International Court of Arbitration has issued a partial award i…